Bacterial Ghost Cancer Immunotherapy - A new standard in tumour therapy based on the bacterial ghost platform technology

ended

MMalignant diseases represent a major health problem in all parts of the world and their incidence, according to the WHO/ IARC World Cancer Report 2014, will increase by 57% worldwide in the next 20 years. Standard treatment strategies for cancer including surgery, chemotherapy and targeted molecular therapy still do not guarantee complete elimination of the disease. In addition, cancer cells exhibited high capability to escape from immunosurveillance after applied treatment which was confirmed with frequently occurred relapse of disease. BIRD-C have developed Bacterial Ghost Cancer Immunotherapy (BGCI) - a novel personalised medicine approach towards vaccination against tumours. BIRD-C’s therapeutic cancer vaccines are based on personalised dendritic cells-based cancer immunotherapy that targets the tumour microenvironment using Bacterial Ghosts (BGs), the proprietary platform technology of BIRD-C. The tumour therapy strategy is to (re)stimulate the patient immune system to revert the tumour evasion and build strong humoral and cellular immune responses against patient-specific tumour antigens. Obtained results show that BGCI can generate effective response to tumours and indicate novel prospective methods for cellular cancer immunotherapy. This approach has been tested in a form of advanced personalised cancer therapy and has improved the survival of patients with solid tumours. During the project, BIRD-C will develop the manufacturing procedure and commercial scale-up strategy and also conduct a multi-centre trial with patients affected by various forms of cancer at different stages of progression to determine the tolerability and effectiveness of the treatment.